Methods of treating ankylosing spondylitis using IL-17 antagonists
AssigneeNovartis AG
InventorsShephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Claims24
A method of treating ankylosing spondylitis (AS), comprising subcutaneously administering to a patient in need thereof about 150 mg-about 300 mg of an IL-17 antibody or antigen-binding fragment thereof every four weeks, wherein the IL-17 antibody or antigen binding-fragment thereof comprises:
- i) an immunoglobulin heavy chain variable (VH) domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin light chain variable (VL) domain comprising the amino acid sequence set forth as SEQ ID NO:
- 10;
- ii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:1-3, respectively;
- and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:4-6, respectively;
- or
- iii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:11-13, respectively;
- and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NO:4-6, respectively.
A method of treating AS in a patient, comprising administering about 150 mg or about 300 mg of secukinumab by subcutaneous injection to the patient every four weeks.
A method of treating active AS in a patient who has responded inadequately to previous treatment with at least one NSAID, comprising administering about 150 mg or about 300 mg of secukinumab by subcutaneous injection to the patient every four weeks.
Dependencies are inferred from the claim text.